Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
135M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
-54.2K
-
Total reported value, excl. options
-
$781M
-
Value change
-
-$3.59M
-
Put/Call ratio
-
0.48
-
Number of buys
-
53
-
Number of sells
-
-50
-
Price
-
$7.70
Significant Holders of Tango Therapeutics, Inc. - Common Stock (TNGX) as of Q3 2024
136 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock as of Q3 2024.
Tango Therapeutics, Inc. - Common Stock (TNGX) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
of 135M outstanding shares and own 75.37% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (16.9M shares), EcoR1 Capital, LLC (13.3M shares), FMR LLC (9.38M shares), Boxer Capital, LLC (8.2M shares), Nextech Invest Ltd. (5.53M shares), T. Rowe Price Investment Management, Inc. (5.02M shares), Southpoint Capital Advisors LP (5M shares), BlackRock, Inc. (4.36M shares), VANGUARD GROUP INC (3.65M shares), and Bain Capital Life Sciences Investors, LLC (2.71M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.